Our product-focused, vertically integrated business model has created a leadership position in several generic drugs. We have a strong presence in ‘first line of defence’ products,includingParacetamol, Ibuprofen, Guaifenesin and Metformin. We export nearly 60% of our revenue to the US and Europe. Our key customers include some of the leading generic, as well as, branded pharmaceutical companies. Our integrated model for manufacturing APIs, PFIs and Finished Dosages enables us to provide products across the value chain and enhances our competitiveness. We have emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Granules Consumer Health (GCH)

GCH, our consumer health division, was established to leverage our efficiencies, scale, integration and relationship management for our core products as well as other large-volume pharmaceutical products.While providing high-quality, cost-effective products has been the key goal at Granules for the past three decades, carrying forward to the retail front will let us work directly with the end customer and provide more innovative solutions. In addition to getting their private label supplies directly from us, retailers will have access to a responsive team that is adamant about making their business easier and more productive.

Granules has initiated two strategic moves by acquiring Auctus Pharma (now, officially amalgamated into Granules and referred to as ‘New API Business’) in February 2014 and by setting up a dedicated R&D center to focus on the development of this vertical. These moves are a part of our diversification strategy to strengthen our focus on vertical integration. The acquisition of Auctus Pharma gave us access to 12 APIs, as well as key intermediates in therapeutic categories, such as anti-histaminic, antihypertensive, anti-thrombotic, proton pump inhibitors, and anti-convulsants, among others. Our R&D centre, while working on making the current processes for existing products within the New API business more efficient has also been adding new APIs to the portfolio. A strong strategic intent of forward integration has been and will be the backbone of this segment.

Granules Pharmaceutical Inc (GPI)

We recently bought a facility in Chantilly, Virginia. Our objective is to focus on formulation R&D by leveraging a niche technologythat enables us to make dosage forms with specific release capabilities like pulsatile drug release in tablet and capsule dosage form, orally disintegrating modified release tablets (XR, MR, ER),modified release suspension and controlled substances capabilities in an abuse deterrent technology platform,all supported by “New API business,” to stay in line with our focus on integration.

We also have ventured into the CRAMS business through Granules-OmniChem, a 50-50 joint venture with Ajinomoto OmniChem - our partner, which is nearly 40 years of experience in CRAMS. Ajinomoto OmniChem works with branded pharmaceutical companies, and makes patent protected products for regulated markets. Going forward, when these products go off-patent, customers will be able to retain market share by shifting to the products made at Granules- OmniChem, by leveraging our expertise in efficient manufacturing.